Status:
RECRUITING
A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer
Lead Sponsor:
Changzhi People's Hospital Affiliated to Changzhi Medical College
Conditions:
Gastric Cancer
RWS
Eligibility:
All Genders
18-75 years
Brief Summary
The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions, particularly in various...
Eligibility Criteria
Inclusion
- Age ≥18 years old, both male and female;
- patients with advanced gastric cancer diagnosed by pathology or histology and progressed or recurred after 6 months of adjuvant therapy can also be considered for enrollment;
- Have at least one measurable lesion on imaging (RECIST 1.1 criteria), the spiral CT or MR target lesion should be ≥10 mm and lymph node ≥15 mm;
- The investigator determines that the patient is amenable to treatment with karelizumab or apatinib;
- Voluntary enrollment; good compliance and willingness to cooperate with follow-up.
Exclusion
- Pregnant or lactating women;
- Previous use of other immunotherapy drugs (e.g. PD-1 monoclonal antibody, PD-L1 monoclonal antibody, CTLA4 monoclonal antibody, etc.);
- Prior use of other anti-angiogenic therapeutic agents (e.g., apatinib, etc.);
- Patients who, in the judgment of the investigator, are not suitable for inclusion.
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
504 Patients enrolled
Trial Details
Trial ID
NCT06485271
Start Date
November 1 2023
End Date
October 1 2026
Last Update
July 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Changzhi People's Hospital Affiliated to Changzhi Medical College
Changzhi, Shanxi, China